News

The non-exclusive license agreement pairs Alcon's PCIOL optical designs with RxSight's post-operative light-adjustable platform, with the aim of allowing surgeons to fine-tune visual outcomes after cataract surgery.

Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.

The FDA issued a nationwide recall of a steroid eye drop.

Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

In this Q&A, Dipanjan Pan, PhD, breaks down the science behind the COSMIC tear biosensor platform and what it will take to bring it to clinical use.

What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.

Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.

The FDA has granted priority review to satralizumab for thyroid eye disease, with a PDUFA date of October 15, 2026, based on phase 3 SatraGO trial data.

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

The agency clears Lumvoa for thyroid eye disease across active and chronic stages, delivering rapid proptosis and diplopia gains with a 12-week IV regimen.

In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.

Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.